{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011601","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.150448+00:00","generated_at":"2026-05-21T00:48:07.642856+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Imunon receives Nasdaq notice for failing to meet $2.5M stockholders' equity requirement","bullets":["Nasdaq notified Imunon on May 19, 2025 of non-compliance with minimum stockholders' equity of $2.5M (Listing Rule 5550(b)(1)).","Company has until July 3, 2025 to submit a compliance plan; if accepted, Nasdaq may grant up to 180 days to regain compliance.","Failure to regain compliance could lead to delisting; company would have right to a hearing before Nasdaq Hearings Panel.","Deficiency is unrelated to prior notice regarding minimum bid price requirement disclosed in November 2024.","Company evaluating options to regain compliance but cautions no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011601","json":"https://secwatch.observer/filing/0001641172-25-011601.json","markdown":"https://secwatch.observer/filing/0001641172-25-011601.md","text":"https://secwatch.observer/filing/0001641172-25-011601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000164117225011601/0001641172-25-011601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000164117225011601/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T00:48:07.642856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60ed4026eba9a11b6006cd255bf3aa27a1a37d5e","claim":"Imunon, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 19, 2025, Imunon, Inc. (“the Company”) received a letter (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is no longer in compliance with the minimum stockholders’ equity requirement (the “Minimum Stockholders’ Equity Requirement”) for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000 or meet the alternative compliance standards relating to the market value of listed securities or ne","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225011601/0001641172-25-011601-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}